Amplification of the MYCN oncogene, which occurs in approximately 20% of cases (Huang and Weiss, 2013), is one of the clearest markers for identifying high-risk neuroblastoma patients, regardless of disease stage. This evidence concerns the gene MYCN and neuroblastoma.